Ikena Oncology, Inc.(IKNA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IKNA Ikena Oncology, Inc.

盘前交易 11-22 04:43:14 EST

1.73

+0.03

+1.76%

最高1.77	最低1.69	成交量8.03万
今开1.69	昨收1.70	日振幅4.76%
总市值8,349万	流通市值2,399万	总股本4,826万
成交额13.87万	换手率0.58%	流通股本1,387万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"IKNA","market":"US","secType":"STK","nameCN":"Ikena Oncology, Inc.","latestPrice":1.73,"timestamp":1732222800000,"preClose":1.7,"halted":0,"volume":80296,"delay":0,"floatShares":13868430,"shares":48258111,"eps":-1.237471,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.03,"latestTime":"11-22 04:43:14 EST","open":1.69,"high":1.771,"low":1.69,"amount":138723.58514,"amplitude":0.047647,"askPrice":1.73,"askSize":700,"bidPrice":1.54,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.237471,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732285800000},"adr":0,"listingDate":1616731200000,"adjPreClose":1.73,"postHourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.73,"latestTime":"16:59 EST","volume":30,"amount":51.3,"timestamp":1732226398017},"volumeRatio":1.764475800748706},"requestUrl":"/m/hq/s/IKNA","defaultTab":"news","newsList":[{"id":"2483383305","title":"Ikena Oncology, Inc.2024财年第三财季实现净利润-10.23百万美元，同比增加41.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483383305","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483383305?lang=zh_cn&edition=full","pubTime":"2024-11-14 00:00","pubTimestamp":1731513631,"startTime":"0","endTime":"0","summary":"11月14日，Ikena Oncology, Inc.公布财报，公告显示公司2024财年第三财季净利润为-10.23百万美元，同比增加41.00%；其中营业收入为0.00美元，每股基本收益为-0.21美元。从资产负债表来看，Ikena Oncology, Inc.总负债14.76百万美元，其中短期债务3.92百万美元，资产负债比为0.11，流动比率为0.16。机构评级：截至2024年11月14日，当前有2家机构对Ikena Oncology, Inc.目标价做出预测，其中目标均价为3.00美元，其中最低目标价为2.00美元，最高目标价为4.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114000100abbe0dab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114000100abbe0dab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKNA"],"gpt_icon":0},{"id":"2481252136","title":"艾克纳肿瘤公司（Ikena Oncology Inc）公布截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2481252136","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481252136?lang=zh_cn&edition=full","pubTime":"2024-11-08 01:20","pubTimestamp":1731000019,"startTime":"0","endTime":"0","summary":"   * Ikena Oncology Inc   报告，截至9月30日的季度调整后每股亏损21美分，高于去年同期的每股-40美分。三位分析师对该季度的平均预期是每股亏损 27 美分。华尔街预期为每股-33美分至-21美分。* Ikena Oncology Inc 公布的季度每股收益为亏损 21 美分。* 本季度，Ikena Oncology Inc 的股价下跌了 0.6%，今年迄今为止下跌了 12.7%。11月7日 - 预测变化   * 在过去三个月中，分析师的平均盈利预期上升了约 2.1%。华尔街对 Ikena Oncology Inc 的 12 个月目标价中位数为 4.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"艾克纳肿瘤公司（Ikena Oncology Inc）公布截至 9 月 30 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKNA","BK4539","BK4007"],"gpt_icon":0},{"id":"2481003716","title":"Ikena Oncology Inc    预计每股亏损 27 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2481003716","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481003716?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:16","pubTimestamp":1730902563,"startTime":"0","endTime":"0","summary":"   * Ikena Oncology Inc    预计在11月7日公布截至2024年9月30日的业绩报告时，季度收入将出现下降(预计)。*    * LSEG的分析师平均预计Ikena Oncology Inc每股亏损27美分。* 华尔街对 Ikena Oncology Inc 的 12 个月目标价中位数为 4.00 美元，高于上一次收盘价 1.69 美元。11月6日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Ikena Oncology Inc    预计每股亏损 27 美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKNA"],"gpt_icon":0},{"id":"2460209249","title":"Ikena Oncology, Inc.2024财年第二财季实现净利润-13.73百万美元，同比增加19.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460209249","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460209249?lang=zh_cn&edition=full","pubTime":"2024-08-17 00:00","pubTimestamp":1723824039,"startTime":"0","endTime":"0","summary":"8月17日，Ikena Oncology, Inc.公布财报，公告显示公司2024财年第二财季净利润为-13.73百万美元，同比增加19.80%；其中营业收入为0.00美元，每股基本收益为-0.28美元。从资产负债表来看，Ikena Oncology, Inc.总负债14.63百万美元，其中短期债务3.70百万美元，资产负债比为0.11，流动比率为0.19。机构评级：截至2024年8月17日，当前有2家机构对Ikena Oncology, Inc.目标价做出预测，其中目标均价为3.00美元，其中最低目标价为2.00美元，最高目标价为4.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000632959f2db3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000632959f2db3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKNA"],"gpt_icon":0},{"id":"2458303062","title":"艾克纳肿瘤公司（Ikena Oncology Inc）公布截至 6 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2458303062","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458303062?lang=zh_cn&edition=full","pubTime":"2024-08-09 08:36","pubTimestamp":1723163801,"startTime":"0","endTime":"0","summary":"   * Ikena Oncology Inc   报告，截至6月底的季度调整后每股亏损28美分，高于去年同期的每股-44美分。四位分析师对该季度的平均预期是每股亏损 35 美分。华尔街预期为每股-42美分至-27美分。* Ikena Oncology Inc 公布的本季度每股收益为亏损 28 美分。* 该公司当季亏损 1373 万美元。* Ikena Oncology Inc 本季度股价下跌了 1.2%，今年迄今为止下跌了 17.3%。8月9日 - 预测变化   * 在过去三个月中，分析师的平均盈利预期上升了约 10.9%。华尔街对 Ikena Oncology Inc 的 12 个月目标价中位数为 4.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKNA","BK4539","BK4007"],"gpt_icon":0},{"id":"2458030306","title":"艾克纳肿瘤公司（Ikena Oncology Inc）公布截至 6 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2458030306","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458030306?lang=zh_cn&edition=full","pubTime":"2024-08-09 08:36","pubTimestamp":1723163801,"startTime":"0","endTime":"0","summary":"   * Ikena Oncology Inc   报告，截至6月底的季度调整后每股亏损28美分，高于去年同期的每股-44美分。四位分析师对该季度的平均预期是每股亏损 35 美分。华尔街预期为每股-42美分至-27美分。* Ikena Oncology Inc 公布的本季度每股收益为亏损 28 美分。* 该公司当季亏损 1373 万美元。* Ikena Oncology Inc 本季度股价下跌了 1.2%，今年迄今为止下跌了 17.3%。8月9日 - 预测变化   * 在过去三个月中，分析师的平均盈利预期上升了约 10.9%。华尔街对 Ikena Oncology Inc 的 12 个月目标价中位数为 4.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"艾克纳肿瘤公司（Ikena Oncology Inc）公布截至 6 月的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKNA","BK4007","BK4539"],"gpt_icon":0},{"id":"2457071256","title":"Ikena Oncology Inc    预计每股亏损 35 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457071256","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457071256?lang=zh_cn&edition=full","pubTime":"2024-08-07 01:49","pubTimestamp":1722966565,"startTime":"0","endTime":"0","summary":"   * Ikena Oncology Inc    预计在8月8日公布截至2024年6月30日的业绩报告时，季度收入将出现下降(预计)。*    * LSEG的分析师平均预计Ikena Oncology Inc每股亏损35美分。* 目前分析师对该公司股票的平均评级为 \"买入\"，建议的细分为 4 个 \"强烈买入 \"或 \"买入\"，1 个 \"持有\"，没有 \"卖出 \"或 \"强烈卖出\"。* 华尔街对 Ikena Oncology Inc 的 12 个月目标价中位数为 4.00 美元，高于其上次收盘价 1.63 美元。8月6日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Ikena Oncology Inc    预计每股亏损 35 美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKNA"],"gpt_icon":0},{"id":"2446365550","title":"Ikena Oncology, Inc.盘中异动 大幅上涨5.18%报1.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446365550","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446365550?lang=zh_cn&edition=full","pubTime":"2024-06-28 00:10","pubTimestamp":1719504626,"startTime":"0","endTime":"0","summary":"北京时间2024年06月28日00时10分，Ikena Oncology, Inc.股票出现波动，股价快速上涨5.18%。Ikena Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.57%。Ikena Oncology, Inc.公司简介：Ikena Oncology Inc 是一家靶向肿瘤公司，为有需要的患者开发精准疗法，针对 Hippo 和 RAS 肿瘤信号网络中的癌症生长、扩散和治疗耐药节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628001027af8f8d5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628001027af8f8d5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKNA","BK4007","BK4539"],"gpt_icon":0},{"id":"2443359937","title":"Ikena Oncology, Inc.盘中异动 快速下挫5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2443359937","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443359937?lang=zh_cn&edition=full","pubTime":"2024-06-13 03:28","pubTimestamp":1718220522,"startTime":"0","endTime":"0","summary":"北京时间2024年06月13日03时28分，Ikena Oncology, Inc.股票出现异动，股价大幅下挫5.52%。Ikena Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.65%。Ikena Oncology, Inc.公司简介：Ikena Oncology Inc 是一家靶向肿瘤公司，为有需要的患者开发精准疗法，针对 Hippo 和 RAS 肿瘤信号网络中的癌症生长、扩散和治疗耐药节点。其其他候选产品是 IK-175 和 IK-595。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613032843941ee233&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613032843941ee233&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKNA","BK4007","BK4539"],"gpt_icon":0},{"id":"2441301512","title":"Ikena Oncology, Inc.盘中异动 大幅下跌5.06%报1.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2441301512","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441301512?lang=zh_cn&edition=full","pubTime":"2024-06-05 00:02","pubTimestamp":1717516953,"startTime":"0","endTime":"0","summary":"北京时间2024年06月05日00时02分，Ikena Oncology, Inc.股票出现波动，股价大幅下挫5.06%。截至发稿，该股报1.69美元/股，成交量9.1239万股，换手率0.19%，振幅3.23%。Ikena Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.73%。Ikena Oncology, Inc.公司简介：Ikena Oncology Inc 是一家靶向肿瘤公司，为有需要的患者开发精准疗法，针对 Hippo 和 RAS 肿瘤信号网络中的癌症生长、扩散和治疗耐药节点。其其他候选产品是 IK-175 和 IK-595。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605000233af8bf1ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605000233af8bf1ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKNA","BK4539","BK4007"],"gpt_icon":0},{"id":"2439642506","title":"Ikena Oncology, Inc.盘中异动 快速拉升5.39%报1.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2439642506","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439642506?lang=zh_cn&edition=full","pubTime":"2024-05-30 21:32","pubTimestamp":1717075952,"startTime":"0","endTime":"0","summary":"北京时间2024年05月30日21时32分，Ikena Oncology, Inc.股票出现异动，股价大幅上涨5.39%。Ikena Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.13%。Ikena Oncology, Inc.公司简介：Ikena Oncology Inc 是一家靶向肿瘤公司，为有需要的患者开发精准疗法，针对 Hippo 和 RAS 肿瘤信号网络中的癌症生长、扩散和治疗耐药节点。其其他候选产品是 IK-175 和 IK-595。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240530213232aef28ff7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240530213232aef28ff7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4539","IKNA"],"gpt_icon":0},{"id":"2439546814","title":"Ikena Oncology, Inc.：H.C. Wainwright将目标价格从11美元下调至4美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2439546814","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439546814?lang=zh_cn&edition=full","pubTime":"2024-05-29 18:08","pubTimestamp":1716977312,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4539","IKNA"],"gpt_icon":0},{"id":"2439590147","title":"美国研究综述-欧特克、McKesson、Microstrategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2439590147","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439590147?lang=zh_cn&edition=full","pubTime":"2024-05-29 15:12","pubTimestamp":1716966778,"startTime":"0","endTime":"0","summary":"    路透5月29日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括欧特克、麦科森和微策略。要闻  * 模拟器件公司  ：雷蒙德-詹姆斯将目标价从215美元上调至260美元 * Autodesk Inc   ：贝尔德将目标价从296美元下调至289美元 * Cencora Inc   ：贝雅将目标价从277美元上调至280美元 * McKesson Corp   ：贝尔德将目标价从671美元上调至679美元 * Microstrategy Inc   ：Canaccord Genuity将目标价从1,590美元上调至2,047美元 以下是路透周三报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0323240290.USD","PDFS","UAL","AKTS","LU1244550221.USD","BK4130","BK4139","NAPA","CAH","IE00B19Z4B17.USD","DOMO","LU1642822529.SGD","TGI","PLMR","LYV","MNMD","HRT","MSTR","LU0006061336.USD","STZ","TAP","RLJ","MYRG","BK4561","CTRE","BK4585","BK4529","LU1978683503.SGD","CRVO","SAGE","ADSK","BK4214","CAVA","IKNA","INSM","TKO","LU0310799852.SGD","BAH","BK4588","IBTX","MCK","COR","CASY","AAL","BK4528","AGIO","IE00B7SZL793.SGD","RSI","ADI","MNRO"],"gpt_icon":0},{"id":"2439590142","title":"美国研究综述-欧特克、McKesson、Microstrategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2439590142","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439590142?lang=zh_cn&edition=full","pubTime":"2024-05-29 15:12","pubTimestamp":1716966778,"startTime":"0","endTime":"0","summary":"    路透5月29日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括欧特克、麦科森和微策略。要闻  * 模拟器件公司  ：雷蒙德-詹姆斯将目标价从215美元上调至260美元 * Autodesk Inc   ：贝尔德将目标价从296美元下调至289美元 * Cencora Inc   ：贝雅将目标价从277美元上调至280美元 * McKesson Corp   ：贝尔德将目标价从671美元上调至679美元 * Microstrategy Inc   ：Canaccord Genuity将目标价从1,590美元上调至2,047美元 以下是路透周三报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAH","CAH","DOMO","LU1978683503.SGD","BK4588","CRVO","RSI","LU0006061336.USD","RLJ","LU0323240290.USD","ADI","IE00B7SZL793.SGD","AAL","MSTR","INSM","MNRO","MYRG","LYV","BK4214","BK4585","COR","CTRE","BK4561","HRT","IKNA","NAPA","ADSK","LU1244550221.USD","IBTX","LU0310799852.SGD","LU1642822529.SGD","BK4139","BK4528","MCK","CASY","AGIO","CAVA","IE00B19Z4B17.USD","SAGE","TAP","MNMD","BK4529","TGI","STZ","PLMR","BK4130","AKTS","PDFS","UAL","TKO"],"gpt_icon":0},{"id":"2439532182","title":"BUZZ-Ikena Oncology跳槽，公司将评估战略选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2439532182","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439532182?lang=zh_cn&edition=full","pubTime":"2024-05-29 06:40","pubTimestamp":1716936009,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    5月28日 - ** 艾克纳肿瘤公司  股票在延时交易中上涨17.3%，至1.56美元 ** 公司称董事会已批准探索、审查和评估一系列潜在战略选择的程序 ** 表示将停止开发试验性药物IK-930** IKNA 将因停药而裁员约 53** 裁员将导致解雇18名员工，预计在2024年第三季度完成- IKNA ** Ikena公司正在评估公司及其研发管线的战略选择。** 股价今年以来下跌了32.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKNA","BK4007","BUZZ","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ikenaoncology.com","stockEarnings":[{"period":"1week","weight":0.0117},{"period":"1month","weight":0.0237},{"period":"3month","weight":0.0058},{"period":"6month","weight":0.3008},{"period":"1year","weight":0.0613},{"period":"ytd","weight":-0.1218}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ikena Oncology, Inc.于2016年3月2日成立为特拉华州公司，总部位于马萨诸塞州波士顿。他们是一家靶向肿瘤公司，专注于开发针对驱动癌症形成和扩散的关键信号通路的新型癌症疗法。他们的项目专注于关键的癌症驱动途径，这些途径在科学文献中得到了很好的验证，但缺乏经批准或有效的治疗方法，因此有可能解决高度未满足的医疗需求。通过利用他们对发现化学、转化科学和以患者为中心的药物开发的深刻理解，他们建立了一个专注于基因定义或生物标记物驱动的癌症的全资和合作项目的深入渠道，使他们能够针对他们认为最有可能的特定患者群体对候选产品的治疗作出反应。自2016年开始运营以来，他们已经发现或开发了5个肿瘤项目，其中包括4个IND研究或临床开发的候选产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.019208},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.121189},{"month":3,"riseRate":0,"avgChangeRate":-0.049427},{"month":4,"riseRate":0.25,"avgChangeRate":0.005061},{"month":5,"riseRate":0.75,"avgChangeRate":0.064667},{"month":6,"riseRate":0.5,"avgChangeRate":-0.033712},{"month":7,"riseRate":0.5,"avgChangeRate":-0.087176},{"month":8,"riseRate":0.5,"avgChangeRate":0.039063},{"month":9,"riseRate":0.25,"avgChangeRate":-0.081793},{"month":10,"riseRate":0,"avgChangeRate":-0.113594},{"month":11,"riseRate":0.5,"avgChangeRate":-0.121724},{"month":12,"riseRate":0.666667,"avgChangeRate":0.142688}],"exchange":"NASDAQ","name":"Ikena Oncology, Inc.","nameEN":"Ikena Oncology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ikena Oncology, Inc.(IKNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ikena Oncology, Inc.(IKNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ikena Oncology, Inc.,IKNA,Ikena Oncology, Inc.股票,Ikena Oncology, Inc.股票老虎,Ikena Oncology, Inc.股票老虎国际,Ikena Oncology, Inc.行情,Ikena Oncology, Inc.股票行情,Ikena Oncology, Inc.股价,Ikena Oncology, Inc.股市,Ikena Oncology, Inc.股票价格,Ikena Oncology, Inc.股票交易,Ikena Oncology, Inc.股票购买,Ikena Oncology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ikena Oncology, Inc.(IKNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ikena Oncology, Inc.(IKNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}